Skip to content

Clinical trials

Premature Birth trials in Italy with no applicable phase

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Premature Birth Phase: Not applicable Country / region: Italy Clear all

52 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20101
20112
20121
20144
20151
20163
20173
20183
20197
20207
20215
20223
20233
20244
20253
20262

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Unknown status21
Completed19
Recruiting4
Terminated3
Active, not recruiting3
Not yet recruiting1
Enrolling by invitation1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Federico II University6
European Institute for Evidence Based Osteopathic Medicine4
University of Turin, Italy4
Fondazione Policlinico Universitario Agostino Gemelli IRCCS3
Ospedale di Circolo - Fondazione Macchi3
University of Florence3
Come Collaboration2
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico2
Thomas Jefferson University2
University Hospital Padova2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Premature Birth52
Respiratory Distress Syndrome4
Obstetric Labor, Premature3
Brain Injuries2
Pain2
Respiratory Aspiration2
Respiratory Distress Syndrome, Newborn2
Apnea1
Blindness, Cortical1
Bronchopulmonary Dysplasia1

Trials

Showing 1 to 25 of 52. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.